Penicillin dosing for pneumococcal pneumonia

C S Bryan1, R Talwani, M S Stinson

  • 1Department of Medicine, University of South Carolina School of Medicine and Richland Memorial Hospital, Columbia 29203, USA.

Chest
|December 24, 1997
PubMed

Insights

Penicillin G is reconsidered for pneumococcal pneumonia due to rising resistance to other antibiotics. Optimized high-dose regimens and precise dosing guidelines are crucial for effective treatment, especially in severe cases.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Penicillin G was historically the primary treatment for pneumococcal pneumonia.
  • Challenges include diagnostic difficulties, increasing drug resistance, and unclear dosing guidelines.
  • Renewed interest in penicillin G is driven by resistance to newer antibiotics like cephalosporins and concerns about vancomycin overuse.

Purpose of the Study:

  • To review issues concerning penicillin G dosing for pneumococcal pneumonia.
  • To propose an optimized high-dose regimen for severe cases.
  • To provide guidance for dose adjustments in specific patient populations.

Main Methods:

  • Review of literature on penicillin G dosing strategies.
  • Analysis of intermittent versus continuous therapy.
  • Examination of dose-response relationships with pneumococcal resistance.
  • Consideration of cost-effective pharmacology.

Main Results:

  • An optimal high-dose regimen involves a loading dose followed by continuous infusion.
  • Specific dosing recommendations are provided for a 70-kg adult with life-threatening pneumonia.
  • A formula is proposed for adjusting maintenance doses in elderly patients and those with renal failure.
  • The proposed regimen achieves serum levels effective against most resistant strains.

Conclusions:

  • Optimized high-dose penicillin G regimens can be effective for pneumococcal pneumonia.
  • Precise dosing is essential, particularly with emerging resistance.
  • Reserve newer antibiotics for specific indications like meningitis, endocarditis, or highly resistant infections.

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...